95
Participants
Start Date
January 11, 2014
Primary Completion Date
November 22, 2018
Study Completion Date
October 3, 2019
OnabotulinumtoxinA
OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
UZ Antwerpen, Antwerp
UZ Leuven, Leuven
University of Ankara, Ankara
Ghent University Hospital, Ghent
Pediatric Urology Associates, PC, Tarrytown
Duke University, Durham
McKay Urology Carolinas Medical Center, Charlotte
Medical University of South Carolina, Charleston
Hopital Pellegrin - Enfants, Bordeaux
University of Alabama at Birmingham Division of Urology Research Office, Birmingham
Cincinnati Children's Hospital Medical Center Cincinnati Center for Clinical Research and Outpatient Clinic, Cincinnati
Riley Hospital for Children, Indianapolis
William Beaumont Hospital Research Institute, Royal Oak
Fakultni nemocnice Hradec Kralove, Hradec Králové
Children's Hospital of Wisconsin Department of Pediatric Urology, Milwaukee
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
St. Louis Children's Hospital Division of Urology, St Louis
Oklahoma Children's Hospital, Oklahoma City
Hôpital Necker Enfants-Malades, Paris
Seconda Università di Napoli, Naples
CHU de Limoges - Hôpital Mère et l'Enfant, Limoges
Cedars-Sinai Medical Center, Los Angeles
Children's Hospital of Orange County, Orange
McMaster University Medical Centre, Hamilton
CHU Sainte Justine, Montreal
Fakultni nemocnice Olomouc, Olomouc
Bambin Gesù- Ospedale Pediatrico, Rome
Copernicus Podmiot Leczniczy Sp. z o. o. Kliniczny Oddział Chirurgii i Urologii Dzieci i Młodzieży GUMed, Gdansk
Specjalistyczny Gabinet Lekarski, Poznan
Medical University of Wroclaw, Wroclaw
Lead Sponsor
Allergan
INDUSTRY